2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium - Friday, November 13, 2020

Join us as we discuss today's pressing healthcare issues.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005244/en/

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

CO-HOSTS:

Bunny Ellerin

Director, HPM, Columbia Business School

Jing He

Biotech Analyst, Gabelli Funds

  • MBA, Harvard Business School
  • BA, Columbia University
  • MBA, Columbia Business School
  • MA, Washington University in St. Louis
  • BS, Peking University

Time

Agenda

9:00 – 9:10 AM

Welcome

  • Bunny Ellerin, Director, Healthcare and Pharmaceutical Management Program

9:10 – 10:00 AM

Vaccines & Therapeutics to Treat COVID-19

  • David Hering, Regional President, North America, Pfizer Vaccines
  • Dr. Robert Paris, Vice President, Infectious Diseases, Moderna
  • Dr. David Weinreich, Senior Vice President, Global Clinical Development, Regeneron
  • (Moderator) Jing He ‘15, Biotech Analyst, Gabelli Funds

10:10 – 11:00 AM

Health Policy & Reimbursement Trends

  • Dr. Deepa Kumaraiah, Senior Vice President, Service Lines and Chief Physician, NYP Medical Groups, NewYork-Presbyterian
  • Melissa Schulman, Senior Vice President of Government Affairs, CVS Health
  • Professor Michael Sparer, Chair, Health Policy and Management, Columbia University Mailman School of Public Health
  • (Moderator) Jeff Jonas, Portfolio Manager, Gabelli Funds

11:10 – Noon

Healthcare Delivery in a Virtual World

  • Dr. Amy Fahrenkopf, President, HSS Health and Senior Vice President, Hospital for Special Surgery
  • Jason Gorevic, CEO, Teladoc Health
  • Dr. Julie Silverstein, Divisional President, Oak Street Health
  • (Moderator) Kevin Kedra, Healthcare Analyst, G.research

Click Here to Register

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc. (NYSE: GBL).

Douglas R. Jamieson
914-921-5020
djamieson@gabelli.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...

Latest Press Releases

Related News